past day pre-announc revenu complet equiti
financ take opportun updat model includ forecast
beyond thought nstg valuat current risk/reward
sell week like improv risk/reward maintain price
target rate
earlier week pre-announc revenu y/i
midpoint guidanc forecast
consensu bad news miss forecast surpris
given low bar seem head quarter note preview-
link note good news ostens function time lam
collabor revenu forecast believ manag
still expect year product servic revenu
ahead manag guidanc ahead forecast
latter instrument revenu better expect place
instrument expect consum revenu line
expect pull-through high end guidanc prosigna revenu
better expect servic revenu better
forecast like driven demand digit spatial profil
thought revenu outlook model updat
reduc forecast revenu
respect time pre-announc
gave us opportun scrub key assumpt forecast follow
key revenu assumpt ncounter placement remain support
trend sprint success growth driver
cdx platform get bit long tooth annual ncounter
consum pull remain could high given sprint mix
shift spend ncounter materi declin collabor revenu
believ count lam develop regulatori fund cdx
opportun seem diminish modestli lower expect prosigna
estim recent equiti financ like provid adequ
fund get much accordingli believ
appropri use price/sal vs ev/sal valuat purpos price/
sale basi current trade line peer group median
ghdx
pleas see page report import disclosur
launch new instrument platform improv assay offer enter
companion diagnost agreement garner financi compens arguabl
unpreced industri continu believ remain role ncounter
technolog lab also believ product platform would well
someon els hand said hard convict outlook given poor
manag visibl appear seri inconsist perform weak
quarterli perform cdx partner increasingli concern
limit clinic instal base believ new cdx partnership tougher find
term resembl enter past year pipelin interest
hard give lot credit next act current act
inconsist accordingli market perform rate pt
prosigna reimburs coverag
collabor companion diagnost
sprint placement grow
sign new collabor
competit regulatori concern
ncounter difficulti penetr
annuiti stream
materi cdx deal sign
decentr market
prosigna growth limit competit
low reimburs
collabor fail develop new
product limit pipelin
found nanostr life scienc tool molecular
diagnost compani base seattl washington nanostr develop product
base novel digit molecular barcod technolog exclus licens
laboratori dr leroy hood institut system biolog technolog
term ncounter allow highli multiplex sensit genet analysi
variou sampl type without need amplif nanostr market technolog
line commerci instrument assay develop varieti
basic research translat vitro diagnost applic includ prosigna
fda-approv vitro diagnost prognosi earli stage breast cancer
forecast includ meaning revenu contribut digit spatial
profil hyb seq forecast base busi fair one would
like need conclud dsp hyb seq potenti worth market
valu revenu p/ purchas share current level
like reason even recogn execut rel target
consist inconsist sinc ipo existing-smal cap public compani tri
move histor challeng accordingli feel comfort
maintain price target
head week risk/reward like balanc recent financ reduc
share price almost past day like improv
risk/reward base logic present albeit level believ would
justifi upgrad base current known
compani report thomson eikon cowen compani
cowen vs consensu mm except revenu reiter margin ex expect gross margin reiter oper net loss per share reiter select revenu metric mm except servic instrument growth consum revenu ex growth prosigna growth servic growth statement mm except ex per count pre-announc revenu forecast consensu slightli midpoint guidanc rel forecast miss attribut collabor revenu came light estim believ compani abl recogn much lam research revenu anticip slight off-set instrument revenu place system forecast beat estim servic revenu also stronger anticip due solid interest digit spatial profil program pre-announc product servic revenu ahead forecast prior guidanc call product servic revenu pre-announc instrument revenu ahead forecast compani indic instal base approxim instrument instrument ahead expect pre-announc consum revenu line forecast impli pull-through guid rang believ revenu quarter slightli stronger manag anticip drove product servic revenu beat prosigna revenu pre-announc ahead forecast pre-announc servic revenu ahead forecast compani indic interest digit spatial profil program strong believ drove upsid rel expect pre-announc collabor revenu forecast prior guidanc call revenu believ lam research revenu come much expect quarter cowen
compani report cowen compani
cagrcommentstot pre-announc revenu revenu reiter product servic pre-announc revenu product servic revenu reiter instrument consum revenu ex prosigna pre-announc revenu may prosigna revenu reiter servic spatial profil access program includ servic revenuecollabor pre-announc revenu collabor revenu reiter instrument base end growth shipment stream expect pull-through reiter research prosigna revenu reiter growth total stream pre-announc revenu collabor revenu lam research revenu least scale throughout year cowen
compani report thomson eikon cowen compani
pre-announc revenu revenu reiter expect gross margin reiter sale ex revenu exclud gm develop expens partial off-set lam reimburs gener sg expens reiter oper net interest expens reiter incom gaap net loss reiter net loss per share reiter share count mm gross oper consensu estim cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
downsid risk includ limit reimburs cut test price delay
weaker expect clinic data support new product competit result
market share eros regulatori hurdl delay difficulti penetr establish
market lack extern panel innov feed product pipelin
upsid risk includ benefit associ chang commerci strategi could
occur sooner current expect pipelin product could drive upsid sooner
current contempl model company-specif challeng could address
larger tool compani better posit optim commerci potenti
ncounter technolog could lead strateg sale price far exce price
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock thermo fisher scientif secur
cowen compani llc manag co-manag public offer past month
cowen compani llc receiv compens invest bank servic nanostr technolog past month
cowen compani llc and/or affili expect receiv intend seek compens invest bank servic next month
nanostr technolog past month client cowen compani llc cowen compani llc provid provid
invest bank servic past month
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
